4.4 Review

Interstitial lung disease in systemic sclerosis: current and future treatment

期刊

RHEUMATOLOGY INTERNATIONAL
卷 37, 期 6, 页码 853-863

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00296-016-3636-7

关键词

Systemic sclerosis; Scleroderma; Interstitial lung disease; Fibrosis; Treatment

资金

  1. FIRA (Fondazione Italiana Ricerca per l'Artrite) [RN1366/2013]

向作者/读者索取更多资源

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc-ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis, diagnosis, prognosis, survival and finally current and future treatment options in SSc-ILD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据